TrakCel has appointed co-founder Dr Fiona Withey as CEO and fellow co-founder Ravi Nalliah to the role of Chief Strategy Officer.
TrakCel has experienced significant growth over the last eight years, establishing itself as a cellular orchestration platform for advanced therapies. TrakCel supports both clinical and commercial therapies globally and multilingually with live deployments of its platform across autologous CAR-T, allogeneic CAR-T, MIL’s (Marrow Infiltrating Lymphocytes), TIL’s (Tumor Infiltrating Lymphocytes), Personalized Cancer Vaccines and Gene Edited CRISPR therapies.
Withey was previously VP of Global Clinical Strategy and Managing Director UK Clinical Services at PCI Pharma Services, prior to which she was CEO of Biotec Services International, a specialist in ultra-low temperature pharma contract services.
Speaking of her appointment, Withey said: “As a TrakCel co-founder and now as CEO I look forward to guiding TrakCel to its next phase of development to support the advanced therapies industry. TrakCel has deep industry experience, a leading product portfolio and a growing customer base.”
As Chief Strategy Officer, Nalliah will be responsible for predicting future strategies for the sector and ensuring that TrakCel continues to innovate to meet the needs of therapeutic developers, manufacturers, caregivers and patients.
“The pace of change and development in the cell and gene therapy market is both exceptional and exciting. I have long been an advocate of moving this industry towards standardisation and look forward to developing TrakCel’s product offering and ensuring that we remain at the forefront of innovation,” explained Nalliah. “Fiona will bring a combination of client focus, operational discipline and strong leadership to the team, ensuring that we continue in our crucial strategic aim of further developing our truly expert team at TrakCel.”
